James T Dalton

List of Publications by Year
in descending order

168 papers	9,821 citations	31976 53 h-index	40979 93 g-index
177 all docs	177 docs citations	177 times ranked	9080 citing authors

#	Article	IF	Citations
1	Chemistry and Structural Biology of Androgen Receptor. Chemical Reviews, 2005, 105, 3352-3370.	47.7	439
2	Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6201-6206.	7.1	367
3	Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007, 109, 399-404.	1.4	367
4	The selective androgen receptor modulator GTxâ€024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a doubleâ€blind, placeboâ€controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 153-161.	7.3	304
5	Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncology, The, 2013, 14, 335-345.	10.7	301
6	Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 146-159.	2.8	272
7	Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies. Annual Review of Medicine, 2011, 62, 265-279.	12.2	268
8	Discovery of Nonsteroidal Androgens. Biochemical and Biophysical Research Communications, 1998, 244, 1-4.	2.1	211
9	Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today, 2007, 12, 241-248.	6.4	192
10	Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit. Journal of Medicinal Chemistry, 2009, 52, 3597-3617.	6.4	191
11	Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor. Journal of Biological Chemistry, 2005, 280, 37747-37754.	3.4	186
12	Favorable Effects of Weak Acids on Negative-Ion Electrospray Ionization Mass Spectrometry. Analytical Chemistry, 2004, 76, 839-847.	6.5	182
13	Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats. Endocrinology, 2005, 146, 4887-4897.	2.8	173
14	Development of selective androgen receptor modulators (SARMs). Molecular and Cellular Endocrinology, 2018, 465, 134-142.	3.2	164
15	Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structureâ"Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 1701-1711.	6.4	162
16	Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 2009, 113, 2637-2645.	1.4	152
17	Pharmacodynamics of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1334-1340.	2.5	140
18	FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 2008, 111, 275-284.	1.4	137

#	Article	IF	Citations
19	Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators. Journal of Medicinal Chemistry, 2004, 47, 993-998.	6.4	132
20	Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling, 2008, 6, nrs.06010.	1.0	129
21	Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Current Oncology Reports, 2016, 18, 37.	4.0	128
22	Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5289-5293.	2.2	117
23	Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2005, 5, 173-188.	3.4	115
24	Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids. Pharmaceutical Research, 2003, 20, 1794-1803.	3.5	112
25	Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer Agents. Journal of Medicinal Chemistry, 2010, 53, 7414-7427.	6.4	111
26	Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5Î±-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia. Endocrinology, 2004, 145, 5420-5428.	2.8	109
27	Estrogen Receptor-Î²-selective Ligands Alleviate High-fat Diet- and Ovariectomy-induced Obesity in Mice. Journal of Biological Chemistry, 2010, 285, 31292-31303.	3.4	109
28	Crystal Structure of the T877A Human Androgen Receptor Ligand-binding Domain Complexed to Cyproterone Acetate Provides Insight for Ligand-induced Conformational Changes and Structure-based Drug Design. Journal of Biological Chemistry, 2007, 282, 13648-13655.	3.4	107
29	Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor. Molecular Pharmacology, 2003, 63, 211-223.	2.3	103
30	Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents. Journal of Medicinal Chemistry, 2012, 55, 7285-7289.	6.4	100
31	Design, Synthesis, and SAR Studies of 4-Substituted Methoxylbenzoyl-aryl-thiazoles Analogues as Potent and Orally Bioavailable Anticancer Agents. Journal of Medicinal Chemistry, 2011, 54, 4678-4693.	6.4	99
32	Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats. Pharmaceutical Research, 2007, 24, 328-335.	3.5	98
33	Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth. Clinical Cancer Research, 2013, 19, 5613-5625.	7.0	98
34	Discovery of 2-Arylthiazolidine-4-carboxylic Acid Amides as a New Class of Cytotoxic Agents for Prostate Cancerâ€. Journal of Medicinal Chemistry, 2005, 48, 2584-2588.	6.4	97
35	Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands. Pharmaceutical Research, 2006, 23, 1641-1658.	3.5	92
36	A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance. Cancer Research, 2018, 78, 265-277.	0.9	91

#	Article	IF	Citations
37	Homology Modeling Using Multiple Molecular Dynamics Simulations and Docking Studies of the Human Androgen Receptor Ligand Binding Domain Bound to Testosterone and Nonsteroidal Ligandsâ€. Journal of Medicinal Chemistry, 2001, 44, 1729-1740.	6.4	90
38	TMPRSS2:ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia. Journal of Clinical Oncology, 2014, 32, 206-211.	1.6	90
39	Design, Synthesis, and Biological Evaluation of Stable Colchicine Binding Site Tubulin Inhibitors as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2014, 57, 7355-7366.	6.4	83
40	A Selective Androgen Receptor Modulator for Hormonal Male Contraception. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 546-553.	2.5	82
41	Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Current Opinion in Supportive and Palliative Care, 2013, 7, 345-351.	1.3	72
42	A Ligand-Based Approach To Identify Quantitative Structureâ^'Activity Relationships for the Androgen Receptor. Journal of Medicinal Chemistry, 2004, 47, 3765-3776.	6.4	71
43	Clinical Pharmacokinetics of 5-Aminolevulinic Acid in Healthy Volunteers and Patients at High Risk for Recurrent Bladder Cancer. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 507-512.	2.5	68
44	The Para Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides Is a Major Structural Determinant of in Vivo Disposition and Activity of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 230-239.	2.5	67
45	Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4113-4117.	2.2	66
46	Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways. Molecular Endocrinology, 2008, 22, 2448-2465.	3.7	65
47	Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorganic and Medicinal Chemistry, 2011, 19, 4782-4795.	3.0	64
48	Chiral Nonsteroidal Affinity Ligands for the Androgen Receptor. 1. Bicalutamide Analogues Bearing Electrophilic Groups in the B Aromatic Ring1. Journal of Medicinal Chemistry, 2000, 43, 581-590.	6.4	62
49	Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Research, 2017, 77, 6282-6298.	0.9	62
50	Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Molecular Biology of the Cell, 2013, 24, 3805-3818.	2.1	61
51	Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. European Journal of Medicinal Chemistry, 2002, 37, 619-634.	5.5	60
52	Effects of a Novel Selective Androgen Receptor Modulator on Dexamethasone-Induced and Hypogonadism-Induced Muscle Atrophy. Endocrinology, 2010, 151, 3706-3719.	2.8	60
53	Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling. PLoS ONE, 2014, 9, e103202.	2.5	57
54	Discovery of 4-Aryl-2-benzoyl-imidazoles as Tubulin Polymerization Inhibitor with Potent Antiproliferative Properties. Journal of Medicinal Chemistry, 2013, 56, 3318-3329.	6.4	55

#	Article	IF	Citations
55	FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma. Clinical Cancer Research, 2010, 16, 3182-3192.	7.0	52
56	Pharmacologic activation of estrogen receptor Î± increases mitochondrial function, energy expenditure, and brown adipose tissue. FASEB Journal, 2017, 31, 266-281.	0.5	52
57	MicroRNAs Are Mediators of Androgen Action in Prostate and Muscle. PLoS ONE, 2010, 5, e13637.	2.5	52
58	Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis. Pharmaceutical Research, 2012, 29, 3040-3052.	3.5	50
59	Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. Cancers, 2016, 8, 108.	3.7	49
60	Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Td (4-C Hormonal Male Contraception. Endocrinology, 2009, 150, 385-395.	2.8	48
61	Use of Intravenous Valproate in Three Pediatric Patients with Nonconvulsive or Convulsive Status Epilepticus. Annals of Pharmacotherapy, 1999, 33, 579-584.	1.9	47
62	Ockham's Razor and Selective Androgen Receptor Modulators (SARMs): Are We Overlooking the Role of 5Â-Reductase?. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 10-13.	3.4	46
63	Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3183-3187.	2.2	46
64	17-Î² Estradiol Protects ARPE-19 Cells from Oxidative Stress through Estrogen Receptor-Î². , 2010, 51, 5278.		46
65	Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE, 2010, 5, e13792.	2.5	45
66	A novel liposomal formulation of flavopiridol. International Journal of Pharmaceutics, 2009, 365, 170-174.	5.2	43
67	Unexpected Binding Orientation of Bulky-B-Ring Anti-Androgens and Implications for Future Drug Targets. Journal of Medicinal Chemistry, 2011, 54, 3973-3976.	6.4	43
68	Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen Receptor. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1323-1333.	2.5	42
69	Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5567-5570.	2.2	41
70	Characterization of in vitro generated metabolites of the selective androgen receptor modulators Sâ€22 and Sâ€23 and in vivo comparison to postâ€administration canine urine specimens. Drug Testing and Analysis, 2010, 2, 589-598.	2.6	41
71	Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opinion on Investigational Drugs, 2006, 15, 377-387.	4.1	39
72	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator Sâ€22 to identify potential targets for routine doping controls. Rapid Communications in Mass Spectrometry, 2011, 25, 2187-2195.	1.5	38

#	Article	IF	Citations
73	Pharmacokinetics ofS-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 747 T modulator. Xenobiotica, 2004, 34, 273-280.	1.1	35
74	Synthesis, in vitro structureâ€“activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorganic and Medicinal Chemistry, 2010, 18, 477-495.	3.0	35
75	ERÎ² Selective Agonist Inhibits Angiotensin-Induced Cardiovascular Pathology in Female Mice. Endocrinology, 2013, 154, 4352-4364.	2.8	34
76	Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharmaceutical Research, 2000, 17, 803-810.	3.5	33
77	Identification of a Novel Phosphorylation Site in Human Androgen Receptor by Mass Spectrometry. Biochemical and Biophysical Research Communications, 2001, 284, 836-844.	2.1	33
78	Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs, 2009, 1, 31-40.	5.2	33
79	A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leukemia and Lymphoma, 2009, 50, 1958-1963.	1.3	32
80	Biological Activity of 4-Substituted Methoxybenzoyl- Aryl-Thiazole: An Active Microtubule Inhibitor. Cancer Research, 2011, 71, 216-224.	0.9	32
81	PHARMACOKINETICS AND METABOLISM OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR IN RATS: IMPLICATION OF MOLECULAR PROPERTIES AND INTENSIVE METABOLIC PROFILE TO INVESTIGATE IDEAL PHARMACOKINETIC CHARACTERISTICS OF A PROPANAMIDE IN PRECLINICAL STUDY. Drug Metabolism and Disposition, 2006, 34, 483-494.	3.3	31
82	CHARACTERIZATION OF THE IN VITRO METABOLISM OF SELECTIVE ANDROGEN RECEPTOR MODULATOR USING HUMAN, RAT, AND DOG LIVER ENZYME PREPARATIONS. Drug Metabolism and Disposition, 2006, 34, 243-253.	3.3	30
83	Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-aryl-thiazole and 2-Aryl-4-benzoyl-imidazole for Improving Oral Bioavailability. Drug Metabolism and Disposition, 2011, 39, 1833-1839.	3.3	30
84	Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorganic and Medicinal Chemistry, 2006, 14, 6525-6538.	3.0	29
85	Comparative lipoprotein metabolism of myristate, palmitate, and stearate in normolipidemic men. Metabolism: Clinical and Experimental, 1996, 45, 1108-1118.	3.4	28
86	Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49Î”CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. Journal of Clinical Pharmacology, 2007, 47, 227-237.	2.0	27
87	Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Therapeutic Drug Monitoring, 2008, 30, 620-627.	2.0	27
88	Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer. Steroids, 2014, 90, 94-100.	1.8	27
89	Tip110, the Human Immunodeficiency Virus Type 1 (HIV-1) Tat-interacting Protein of 110 kDa as a Negative Regulator of Androgen Receptor (AR) Transcriptional Activation. Journal of Biological Chemistry, 2004, 279, 21766-21773.	3.4	26
90	Effects of Selective Androgen Receptor Modulator (SARM) Treatment in Osteopenic Female Rats. Pharmaceutical Research, 2009, 26, 2471-2477.	3.5	26

#	Article	IF	Citations
91	A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharmaceutical Research, 1991, 08, 168-173.	3.5	25
92	Estrogen receptor Î² selective nonsteroidal estrogens: seeking clinical indications. Expert Opinion on Therapeutic Patents, 2010, 20, 507-534.	5.0	25
93	Cancer cachexia therapy: a key weapon in the fight against cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 268-273.	2.5	25
94	Discovery and Mechanistic Characterization of a Novel Selective Nuclear Androgen Receptor Exporter for the Treatment of Prostate Cancer. Cancer Research, 2010, 70, 842-851.	0.9	24
95	Nonsteroidal Selective Androgen Receptor Modulators Enhance Female Sexual Motivation. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 439-448.	2.5	24
96	Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochemical Pharmacology, 1999, 58, 1259-1267.	4.4	23
97	Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. Journal of Clinical Investigation, 2021, 131, .	8.2	23
98	In Vitroandin VivoStructure-Activity Relationships of Novel Androgen Receptor Ligands with Multiple Substituents in the B-Ring. Endocrinology, 2005, 146, 5444-5454.	2.8	22
99	Toremifene â€“ a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion on Investigational Drugs, 2006, 15, 293-305.	4.1	22
100	Inhibitors of Tubulin Assembly Identified through Screening a Compound Library. Chemical Biology and Drug Design, 2008, 72, 513-524.	3.2	22
101	Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. Journal of Mass Spectrometry, 2010, 45, 1160-1166.	1.6	22
102	Androgen receptor antagonists: a patent review (2008 â€“ 2011). Expert Opinion on Therapeutic Patents, 2012, 22, 541-565.	5.0	22
103	Time-Variant Increase in Methylprednisolone Clearance in Patients with Acute Respiratory Distress Syndrome: A Population Pharmacokinetic Study. Journal of Clinical Pharmacology, 2001, 41, 415-424.	2.0	21
104	Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Research, 2007, 27, 883-8.	1.1	21
105	Synthesis of novel iodo derived bicalutamide analogs. Tetrahedron Letters, 2004, 45, 9475-9477.	1.4	20
106	SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: A novel class of cytotoxic agents for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4010-4013.	2.2	20
107	INTERSPECIES DIFFERENCES IN PHARMACOKINETICS AND METABOLISM OF S-3-(4-ACETYLAMINO-PHENOXY)-2-HYDROXY-2-METHYL-N-(4-NITRO-3-TRIFLUOROMETHYLPHENYL)-PROPIONAMIDE: THE ROLE OF N-ACETYLTRANSFERASE. Drug Metabolism and Disposition, 2006, 34, 254-260.	3.3	20
108	Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorganic and Medicinal Chemistry, 2006, 14, 5699-5710.	3.0	20

#	Article	IF	Citations
109	A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 293-304.	2.3	20
110	Predictive ability of level A in vitro-in vivo correlation for ringcap controlled-release acetaminophen tablets. Pharmaceutical Research, 2001, 18, 1729-1734.	3.5	19
111	I-387, a Novel Antimitotic Indole, Displays a Potent In vitro and In vivo Antitumor Activity with Less Neurotoxicity. Molecular Cancer Therapeutics, 2010, 9, 2859-2868.	4.1	19
112	Orally Bioavailable Tubulin Antagonists for Paclitaxel-Refractory Cancer. Pharmaceutical Research, 2012, 29, 3053-3063.	3.5	19
113	Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation. PLoS ONE, 2013, 8, e83380.	2.5	19
114	The long and winding road for selective androgen receptor modulators. British Journal of Clinical Pharmacology, 2017, 83, 2131-2133.	2.4	19
115	Domain Structure and DNA Binding Regions of Î² Protein from Bacteriophage Î». Journal of Biological Chemistry, 2006, 281, 25205-25214.	3.4	18
116	In Vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs. Drug Metabolism and Disposition, 2006, 34, 1713-1721.	3.3	18
117	Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Investigational New Drugs, 2016, 34, 458-467.	2.6	18
118	Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4919-4923.	2.2	17
119	Synthesis, Calpain Inhibitory Activity, and Cytotoxicity of P2-Substituted Proline and Thiaproline Peptidyl Aldehydes and Peptidyl Î±-Ketoamides. Journal of Medicinal Chemistry, 2006, 49, 5282-5290.	6.4	17
120	Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 341-341.	1.4	17
121	Medetomidine Analogs as Î±2-Adrenergic Ligands. 2. Design, Synthesis, and Biological Activity of Conformationally Restricted Naphthalene Derivatives of Medetomidine. Journal of Medicinal Chemistry, 1996, 39, 3001-3013.	6.4	16
122	Medetomidine Analogs as Î±2-Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with Î±2-Adrenoceptors Involving a â€œMethyl Pocketâ€• Journal of Medicinal Chemistry, 1997, 40, 3014-3024.	6.4	16
123	Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 868, 110-115.	2.3	16
124	Drug Metabolism and Pharmacokinetics of 4-Substituted Methoxybenzoyl-aryl-thiazoles. Drug Metabolism and Disposition, 2010, 38, 2032-2039.	3.3	16
125	Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian Journal of Andrology, 2014, 16, 256.	1.6	16
126	FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.. Blood, 2006, 108, 2095-2095.	1.4	16

#	Article	IF	Citations
127	Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. European Urology, 2015, 67, 334-341.	1.9	15
128	Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-Nâ†'O shift of disubstituted phenyl ring of a bicalutamide derivative. Tetrahedron Letters, 2006, 47, 3941-3944.	1.4	14
129	A bifunctional colchicinoid that binds to the androgen receptor. Molecular Cancer Therapeutics, 2007, 6, 2328-2336.	4.1	14
130	Role and pharmacologic significance of cytochrome Pâ€450 2D6 in oxidative metabolism of toremifene and tamoxifen. International Journal of Cancer, 2013, 132, 1475-1485.	5.1	14
131	Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. Chirality, 2009, 21, 578-583.	2.6	13
132	Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats. Xenobiotica, 2013, 43, 993-1009.	1.1	13
133	Comparison of High-Dose Intermittent and Low-Dose Continuous Oral Artemisinin in Dogs With Naturally Occurring Tumors. Journal of the American Animal Hospital Association, 2014, 50, 390-395.	1.1	13
134	Alanine Aminotransferase Regulation by Androgens in Non-hepatic Tissues. Pharmaceutical Research, 2012, 29, 1046-1056.	3.5	12
135	Cytochrome P-450 2C9 Sensitizes Human Prostate Tumor Cells to Cyclophosphamide via a Bystander Effect. Antimicrobial Agents and Chemotherapy, 2000, 44, 2659-2663.	3.2	11
136	Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Letters, 2005, 46, 4821-4823.	1.4	11
137	Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sciences, 2006, 79, 1081-1093.	4.3	11
138	Î²-LGND2, an ERÎ² Selective Agonist, Inhibits Pathologic Retinal Neovascularization. , 2012, 53, 5066.		11
139	Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERÎ± Agonist for Hormone Therapy in Prostate Cancer. Endocrinology, 2012, 153, 1070-1081.	2.8	11
140	Effects of bladder resorption on pharmacokinetic data analysis. Journal of Pharmacokinetics and Pharmacodynamics, 1994, 22, 183-205.	0.6	10
141	High-performance liquid chromatographic determination of mitomycin C in rat and human plasma and urine. Biomedical Applications, 1989, 495, 330-337.	1.7	9
142	Pentamidine congeners. 4. DNA binding affinity and anti-Pneumocystis carinii activity of butamidine analogues. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1967-1970.	2.2	9
143	Synthesis of oxazolidinedione derived bicalutamide analogs. Tetrahedron Letters, 2006, 47, 3953-3955.	1.4	9
144	GTx-822, an ERÎ²-Selective Agonist, Protects Retinal Pigment Epithelium (ARPE-19) from Oxidative Stress by Activating MAPK and PI3-K Pathways. , 2010, 51, 5934.		9

#	Article	IF	Citations
145	Recombinant Expression and Purification of Human Androgen Receptor in a Baculovirus System. Biochemical and Biophysical Research Communications, 2001, 284, 828-835.	2.1	8
146	Mass Spectrometric Characterization of the Human Androgen Receptor Ligand-Binding Domain Expressed in Escherichia coli. Biochemistry, 2001, 40, 10756-10763.	2.5	8
147	Preclinical Pharmacology of a Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 402-408.	2.5	8
148	Biotransformation of a Novel Antimitotic Agent, I-387, by Mouse, Rat, Dog, Monkey, and Human Liver Microsomes and In Vivo Pharmacokinetics in Mice. Drug Metabolism and Disposition, 2011, 39, 636-643.	3.3	8
149	High-performance liquid chromatographic determination of pentamidine in plasma. Biomedical Applications, 1993, 622, 255-261.	1.7	7
150	Development and validation of a rapid and sensitive high-performance liquid chromatographyâ€“mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 871, 15-21.	2.3	7
151	Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134. Clinical Cancer Research, 2011, 17, 4693-4704.	7.0	7
152	Drug interaction potential of toremifene andN-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica, 2011, 41, 851-862.	1.1	7
153	Pharmacokinetics of aminolevulinic acid after intravesical administration to dogs. Pharmaceutical Research, 1999, 16, 288-295.	3.5	5
154	Efficient Microwave Enhanced Synthesis of 4-Thiazolidinones. Synlett, 2004, 2004, 2357-2358.	1.8	4
155	Flavopiridol in Chronic Lymphocytic Leukemia. Clinical Leukemia, 2007, 1, 292-297.	0.2	4
156	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. Clinical Pharmacokinetics, 2013, 52, 705-712.	3.5	4
157	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. Blood, 2006, 108, 2845-2845.	1.4	4
158	Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. Cancer Chemotherapy and Pharmacology, 1996, 37, 472-478.	2.3	3
159	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. Blood, 2007, 110, 3104-3104.	1.4	3
160	Effect of para halogen modification of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides on metabolism and clearance. Archives of Pharmacal Research, 2014, 37, 1464-1476.	6.3	2
161	Androgen Receptor. , 2010, , 143-182.		1
162	Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer. International Journal of Oncology, 2012, 41, 337-44.	3.3	1

#	Article	IF	Citations
163	Synthesis and Antiproliferative Activity of 2-Aryl-4-oxo-thiazolidin-3-yl-amides for Prostate Cancer.. ChemInform, 2005, 36, no.	0.0	0
164	Chemistry and Structural Biology of Androgen Receptor. ChemInform, 2005, 36, no.	0.0	0
165	Selective Estrogen Receptor Modulators (SERMs) and Selective Androgen Receptor Modulators (SARMs). , 2015, , 205-227.		0
166	Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).. Blood, 2006, 108, 4578-4578.	1.4	0
167	FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.. Blood, 2009, 114, 3728-3728.	1.4	0
168	Activity of VERU-111, an novel oral Î± and Î² tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 302-302.	1.6	0